Literature DB >> 33178735

Biology-and Location-Oriented Precision Treatment of Rectal Cancer: Present and Future.

Stefan Fichtner-Feigl1.   

Abstract

BACKGROUND: The surgical approach in rectal cancer treatment has evolved in the last decades and a standardized surgical technique for tumor resection - total mesorectal excision - has been established.
SUMMARY: In a multidisciplinary effort with the use of total mesorectal excision in combination with adjuvant and neoadjuvant treatments to compliment surgery disease management can achieve excellent long-term local control and improved patient survival. Further improvements in imaging techniques and the ability to identify prognostic factors such as tumor regression, extramural venous invasion, and threatened margins have introduced the concept of decision-making based on preoperative staging information. KEY MESSAGE: Therefore, in the modern era treatment algorithms are based on high-resolution imaging to plan neoadjuvant therapy and precision surgery followed by pathological and molecular analysis to stratify patients for the need of adjuvant chemotherapy. Despite excellent results with guideline structured treatment pathways, there is still a need to improve long-term results especially for individuals with locally advanced or metastatic tumors.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Chemoradiation; Multimodal therapy; Rectal cancer

Year:  2020        PMID: 33178735      PMCID: PMC7590750          DOI: 10.1159/000510488

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  66 in total

Review 1.  Multidisciplinary Management of Locally Advanced Rectal Cancer--An Evolving Landscape?

Authors:  Margaret Lee; Peter Gibbs; Rachel Wong
Journal:  Clin Colorectal Cancer       Date:  2015-06-17       Impact factor: 4.481

2.  Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial.

Authors:  Sung-Bum Kang; Ji Won Park; Seung-Yong Jeong; Byung Ho Nam; Hyo Seong Choi; Duck-Woo Kim; Seok-Byung Lim; Taek-Gu Lee; Dae Yong Kim; Jae-Sung Kim; Hee Jin Chang; Hye-Seung Lee; Sun Young Kim; Kyung Hae Jung; Yong Sang Hong; Jee Hyun Kim; Dae Kyung Sohn; Dae-Hyun Kim; Jae Hwan Oh
Journal:  Lancet Oncol       Date:  2010-06-16       Impact factor: 41.316

Review 3.  Short-course radiotherapy with immediate or delayed surgery in rectal cancer: A meta-analysis.

Authors:  Haoyan Wu; Chao Fang; Libin Huang; Chuanwen Fan; Cun Wang; Lie Yang; Yuan Li; Zongguang Zhou
Journal:  Int J Surg       Date:  2018-05-25       Impact factor: 6.071

4.  Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Pelagia Tsoutsou; Nikolaos Lyratzopoulos; Michael Pitiakoudis; George Kouklakis; Pelagia A Chloropoulou; Kostantinos Manolas; Efthimios Sivridis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-30       Impact factor: 7.038

Review 5.  Using immunotherapy to boost the abscopal effect.

Authors:  Wilfred Ngwa; Omoruyi Credit Irabor; Jonathan D Schoenfeld; Jürgen Hesser; Sandra Demaria; Silvia C Formenti
Journal:  Nat Rev Cancer       Date:  2018-02-16       Impact factor: 60.716

6.  Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

Authors:  Andrea Cercek; Campbell S D Roxburgh; Paul Strombom; J Joshua Smith; Larissa K F Temple; Garrett M Nash; Jose G Guillem; Philip B Paty; Rona Yaeger; Zsofia K Stadler; Kenneth Seier; Mithat Gonen; Neil H Segal; Diane L Reidy; Anna Varghese; Jinru Shia; Efsevia Vakiani; Abraham J Wu; Christopher H Crane; Marc J Gollub; Julio Garcia-Aguilar; Leonard B Saltz; Martin R Weiser
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

7.  COLOR II. A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer.

Authors:  M Buunen; H J Bonjer; W C J Hop; E Haglind; G Kurlberg; J Rosenberg; A M Lacy; M A Cuesta; A D'Hoore; A Fürst; J F Lange; P Jess; O Bulut; P Poornoroozy; K Juul Jensen; M Mark Christensen; E Lundhus; H Ovesen; D Birch; I Iesalnieks; C Jäger; M Kreis; Y van riet; E van der Harst; M F Gerhards; W A Bemelman; B M E Hansson; P A Neijenhuis; H A Prins; C Balague; E Targarona; J A Luján Mompeán; J D Franco Osorio; F J Garcia Molina; S Skullman; Z Läckberg; U Kressner; P Matthiessen; S H Kim; A Alfredo Poza
Journal:  Dan Med Bull       Date:  2009-05

8.  Prolongation of the disease-free interval in surgically treated rectal carcinoma.

Authors: 
Journal:  N Engl J Med       Date:  1985-06-06       Impact factor: 91.245

Review 9.  Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.

Authors:  Kevin J Harrington; Igor Puzanov; J Randolph Hecht; F Stephen Hodi; Zsolt Szabo; Swami Murugappan; Howard L Kaufman
Journal:  Expert Rev Anticancer Ther       Date:  2015       Impact factor: 4.512

10.  Multicentre study of short-course radiotherapy and transanal endoscopic microsurgery for early rectal cancer.

Authors:  C J Smart; S Korsgen; J Hill; D Speake; B Levy; M Steward; J I Geh; J Robinson; D Sebag-Montefiore; S P Bach
Journal:  Br J Surg       Date:  2016-05-05       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.